Literature DB >> 9707624

A genetic defect resulting in mild low-renin hypertension.

R C Wilson1, S Dave-Sharma, J Q Wei, V R Obeyesekere, K Li, P Ferrari, Z S Krozowski, C H Shackleton, L Bradlow, T Wiens, M I New.   

Abstract

Severe low-renin hypertension has few known causes. Apparent mineralocorticoid excess (AME) is a genetic disorder that results in severe juvenile low-renin hypertension, hyporeninemia, hypoaldosteronemia, hypokalemic alkalosis, low birth weight, failure to thrive, poor growth, and in many cases nephrocalcinosis. In 1995, it was shown that mutations in the gene (HSD11B2) encoding the 11beta-hydroxysteroid dehydrogenase type 2 enzyme (11beta-HSD2) cause AME. Typical patients with AME have defective 11beta-HSD2 activity, as evidenced by an abnormal ratio of cortisol to cortisone metabolites and by an exceedingly diminished ability to convert [11-3H]cortisol to cortisone. Recently, we have studied an unusual patient with mild low-renin hypertension and a homozygous mutation in the HSD11B2 gene. The patient came from an inbred Mennonite family, and though the mutation identified her as a patient with AME, she did not demonstrate the typical features of AME. Biochemical analysis in this patient revealed a moderately elevated cortisol to cortisone metabolite ratio. The conversion of cortisol to cortisone was 58% compared with 0-6% in typical patients with AME whereas the normal conversion is 90-95%. Molecular analysis of the HSD11B2 gene of this patient showed a homozygous C-->T transition in the second nucleotide of codon 227, resulting in a substitution of proline with leucine (P227L). The parents and sibs were heterozygous for this mutation. In vitro expression studies showed an increase in the Km (300 nM) over normal (54 nM). Because approximately 40% of patients with essential hypertension demonstrate low renin, we suggest that such patients should undergo genetic analysis of the HSD11B2 gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707624      PMCID: PMC21485          DOI: 10.1073/pnas.95.17.10200

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  11 beta-Hydroxysteroid dehydrogenase activity in the renal target cells of aldosterone.

Authors:  A Náray-Fejes-Tóth; C O Watlington; G Fejes-Tóth
Journal:  Endocrinology       Date:  1991-07       Impact factor: 4.736

2.  Combined radioimmunoassay of four steroids in one ml of plasma: II. Androgens.

Authors:  G E Abraham; F S Manlimos; M Solis; A C Wickman
Journal:  Clin Biochem       Date:  1975-12       Impact factor: 3.281

3.  Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research.

Authors:  C H Shackleton
Journal:  J Steroid Biochem Mol Biol       Date:  1993-04       Impact factor: 4.292

4.  Minealocorticoid receptors and 11 beta-steroid dehydrogenase activity in renal principal and intercalated cells.

Authors:  A Náray-Fejes-Tóth; E Rusvai; G Fejes-Tóth
Journal:  Am J Physiol       Date:  1994-01

Review 5.  11 beta-Hydroxysteroid dehydrogenase in renal collecting duct cells.

Authors:  A Náray-Fejes-Tóth; G Fejes-Tóth
Journal:  Steroids       Date:  1994-02       Impact factor: 2.668

6.  Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme.

Authors:  A L Albiston; V R Obeyesekere; R E Smith; Z S Krozowski
Journal:  Mol Cell Endocrinol       Date:  1994-11       Impact factor: 4.102

7.  Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.

Authors:  H Nikkilä; G M Tannin; M I New; N F Taylor; G Kalaitzoglou; C Monder; P C White
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

8.  Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta.

Authors:  Z Krozowski; J A MaGuire; A N Stein-Oakley; J Dowling; R E Smith; R K Andrews
Journal:  J Clin Endocrinol Metab       Date:  1995-07       Impact factor: 5.958

9.  The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase.

Authors:  M Lombes; S Kenouch; A Souque; N Farman; M E Rafestin-Oblin
Journal:  Endocrinology       Date:  1994-09       Impact factor: 4.736

Review 10.  Rapid deoxyribonucleic acid analysis by allele-specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase gene.

Authors:  R C Wilson; J Q Wei; K C Cheng; A B Mercado; M I New
Journal:  J Clin Endocrinol Metab       Date:  1995-05       Impact factor: 5.958

View more
  21 in total

1.  In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence.

Authors:  Jonathan R Manning; Matthew A Bailey; Dinesh C Soares; Donald R Dunbar; John J Mullins
Journal:  Physiol Genomics       Date:  2010-06-22       Impact factor: 3.107

2.  Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  M I New; R C Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.

Authors:  Mabel Yau; Shozeb Haider; Ahmed Khattab; Chen Ling; Mehr Mathew; Samir Zaidi; Madison Bloch; Monica Patel; Sinead Ewert; Wafa Abdullah; Aysenur Toygar; Vitalii Mudryi; Maryam Al Badi; Mouch Alzubdi; Robert C Wilson; Hanan Said Al Azkawi; Hatice Nur Ozdemir; Wahid Abu-Amer; Jozef Hertecant; Maryam Razzaghy-Azar; John W Funder; Aisha Al Senani; Li Sun; Se-Min Kim; Tony Yuen; Mone Zaidi; Maria I New
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

Review 4.  Genetics of the mineralocorticoid system in primary hypertension.

Authors:  Paolo Ferrari
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

5.  Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.

Authors:  M Palermo; G Delitala; F Mantero; P M Stewart; C H Shackleton
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

6.  Blood pressure and human genetic variation in the general population.

Authors:  Pankaj Arora; Christopher Newton-Cheh
Journal:  Curr Opin Cardiol       Date:  2010-05       Impact factor: 2.161

Review 7.  Genetics of arterial hypertension and hypotension.

Authors:  Dieter Rosskopf; Markus Schürks; Christian Rimmbach; Rafael Schäfers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-30       Impact factor: 3.000

Review 8.  Hypertension and adrenal disorders.

Authors:  Wassim Chemaitilly; Robert C Wilson; Maria I New
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

9.  11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.

Authors:  Carmen Campino; Cristian A Carvajal; Javiera Cornejo; Betty San Martín; Oliviero Olivieri; Giancesare Guidi; Giovanni Faccini; Francesco Pasini; Javiera Sateler; Rene Baudrand; Lorena Mosso; Gareth I Owen; Alexis M Kalergis; Oslando Padilla; Carlos E Fardella
Journal:  Endocrine       Date:  2009-10-31       Impact factor: 3.633

10.  Antenatal dexamethasone treatment leads to changes in gene expression in a murine late placenta.

Authors:  B Baisden; S Sonne; R M Joshi; V Ganapathy; P S Shekhawat
Journal:  Placenta       Date:  2007-06-07       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.